Akhtar Amin, MD
Interventional Cardiology · Bowling Green, KYNPI 1063863439
Payments from drug & device makers
Across 184 payments — averaging $47.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Boston Scientific$767
- Abiomed$730
- Chiesi USA, Inc.$268
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$265
- E.r. Squibb & Sons, L.L.C.$238
- plus $2K from 28 others
What the payments were for
- Travel & lodging$3,74743%
- Food & beverage$4,64353%
- Education$2903%
- Gifts$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 49 | $4,866 |
| Boston Scientific | 4 | $767 |
| Abiomed | 25 | $730 |
| Chiesi USA, Inc. | 6 | $268 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $265 |
| E.r. Squibb & Sons, L.L.C. | 20 | $238 |
| Shockwave Medical, Inc | 3 | $227 |
| Abbott | 6 | $212 |
| Pfizer | 10 | $185 |
| Inari Medical, Inc. | 1 | $91 |
| Johnson & Johnson | 5 | $80 |
| Heartflow, Inc. | 4 | $66 |
| Biotronik Inc. | 1 | $60 |
| ZOLL Circulation Inc | 2 | $59 |
| Penumbra, Inc. | 1 | $56 |
| Baxter Healthcare | 2 | $53 |
| La Jolla Pharmaceutical Company | 2 | $51 |
| Stryker | 1 | $49 |
| Philips North America LLC | 3 | $45 |
| AstraZeneca | 3 | $44 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Cardiva Medical, Inc. | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Bayer | 2 | $34 |
| Merck | 1 | $34 |
| Grifols USA, LLC | 2 | $29 |
| Thrombolex, Inc. | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Electromed, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,763 in reported general payments places this provider in the 45th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $138,870 |
| JardianceEmpagliflozin | 65 | $66,919 |
| EntrestoSacubitril/Valsartan | 53 | $64,283 |
| FarxigaDapagliflozin Propanediol | 52 | $44,686 |
| BrilintaTicagrelor | 51 | $32,909 |
| XareltoRivaroxaban | 36 | $29,948 |
| Dofetilide | 25 | $6,367 |
| Bumetanide | 111 | $4,991 |
| Metoprolol Succinate | 267 | $3,452 |
| Atorvastatin Calcium | 351 | $2,169 |
| Carvedilol | 271 | $1,694 |
| Losartan Potassium | 224 | $1,482 |
| Ranolazine ErRanolazine | 19 | $1,402 |
| ClopidogrelClopidogrel Bisulfate | 175 | $1,326 |
| Rosuvastatin Calcium | 137 | $1,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $185 | $138,870137 claims |
| AstraZenecaFarxiga, Brilinta | $44 | $77,595103 claims |
| Boehringer IngelheimJardiance | $16 | $66,91965 claims |
| NovartisEntresto | $14 | $64,28353 claims |
| Johnson & JohnsonXarelto | $80 | $29,94836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Bowling Green
- Jerry RoyBowling Green$180K
- Rahil RafeedheenBowling Green$31K
- Sandeep ChhabraBowling Green$18K
- Mohammed KazimuddinBowling Green$17K
- Thomas TuLouisville$1.4M
- Amit SrivastavaEdgewood$736K
- Avichai EresLexington$616K
- Naresh SolankhiLouisville$545K
- Sreedevi GondiLouisville$535K
- Steve LinLexington$372K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.